ERAS
Erasca, Inc. NASDAQ Listed Jul 16, 2021$13.67
Pre-mkt
$14.07
+2.93%
Mkt Cap $4.3B
52w Low $1.21
54.0% of range
52w High $24.28
50d MA $13.77
200d MA $8.55
P/E (TTM)
—
EV/EBITDA
—
P/B
11.9x
Debt/Equity
0.1x
ROE
-38.3%
P/FCF
-40.6x
RSI (14)
55.50
ATR (14)
$1.14
Beta
1.05
50d MA
$13.77
200d MA
$8.55
Avg Volume
4.8M
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
10835 Road to the Cure · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.11 | -0.10 | +9.1% | 14.65 | +3.4% | -7.0% | -0.8% | -1.1% | +1.0% | +13.0% | — |
| Nov 12, 2025 | AMC | -0.11 | -0.11 | +0.0% | 2.65 | +0.0% | -4.2% | +1.6% | +11.2% | -0.3% | -3.5% | — |
| Aug 12, 2025 | AMC | -0.12 | -0.12 | +0.0% | 1.56 | -0.6% | +3.8% | -3.1% | +4.5% | -6.7% | -0.7% | — |
| May 13, 2025 | AMC | -0.12 | -0.11 | +8.3% | 1.33 | +2.3% | -4.5% | +0.0% | +1.6% | -4.7% | +4.1% | — |
| Mar 20, 2025 | AMC | -0.12 | -0.11 | +8.3% | 1.48 | +0.0% | +3.4% | -2.6% | -0.7% | +0.0% | +4.7% | — |
| Nov 12, 2024 | AMC | -0.17 | -0.11 | +35.3% | 2.99 | +2.3% | -4.7% | -1.4% | -5.0% | +2.2% | +2.2% | — |
| Aug 12, 2024 | AMC | -0.17 | -0.29 | -70.6% | 2.59 | +4.2% | +0.4% | -0.4% | +4.6% | +3.3% | -1.8% | — |
| May 8, 2024 | AMC | -0.21 | -0.23 | -9.5% | 2.15 | -0.5% | -8.8% | -5.6% | +2.7% | -2.1% | +1.6% | — |
| Mar 27, 2024 | AMC | -0.24 | -0.20 | +16.7% | 2.06 | +17.5% | +0.0% | +4.9% | -0.5% | +0.9% | -3.7% | — |
| Nov 9, 2023 | AMC | -0.21 | -0.20 | +4.8% | 2.01 | +5.5% | +0.0% | -3.5% | +11.3% | +7.4% | -4.3% | — |
| Aug 10, 2023 | AMC | -0.27 | -0.21 | +22.2% | 2.60 | +2.3% | +11.9% | -9.6% | -3.2% | -1.8% | +0.4% | — |
| May 15, 2023 | AMC | -0.30 | -0.22 | +26.7% | 2.96 | -0.7% | -4.1% | +1.4% | -4.2% | +0.0% | +5.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4 | BofA Securities | Upgrade | Underperform → Neutral | $16 | $13.18 | $13.54 | +2.7% | +0.7% | -9.8% | +7.5% | +4.2% | -0.3% |
| Apr 27 | Stifel | Maintains | Buy → Buy | — | $21.49 | $20.70 | -3.7% | -10.9% | -48.3% | -8.0% | +16.9% | -5.8% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $13.36 | $13.36 | +0.0% | +1.0% | +13.0% | -4.3% | -1.9% | +2.4% |
| Mar 16 | Guggenheim | Maintains | Buy → Buy | — | $13.62 | $14.15 | +3.9% | -0.8% | -1.1% | +1.0% | +13.0% | -4.3% |
| Mar 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.65 | $15.15 | +3.4% | -7.0% | -0.8% | -1.1% | +1.0% | +13.0% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.65 | $15.15 | +3.4% | -7.0% | -0.8% | -1.1% | +1.0% | +13.0% |
| Mar 13 | Mizuho | Maintains | Outperform → Outperform | — | $14.65 | $15.15 | +3.4% | -7.0% | -0.8% | -1.1% | +1.0% | +13.0% |
| Mar 6 | Clear Street | Maintains | Buy → Buy | — | $15.54 | $15.58 | +0.3% | -0.5% | +1.9% | -1.1% | -0.5% | -5.5% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.96 | $9.24 | -7.2% | -3.5% | +9.3% | -3.5% | +1.8% | +1.9% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.56 | $9.52 | -0.4% | +0.6% | +2.0% | +2.4% | +2.4% | -3.2% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.23 | $6.18 | -0.8% | +20.5% | +10.7% | +15.0% | +0.6% | +2.0% |
| Dec 9 | Mizuho | Maintains | Outperform → Outperform | — | $3.34 | $3.43 | +2.7% | -1.2% | -1.2% | +3.7% | +6.5% | -4.7% |
| Nov 14 | Guggenheim | Maintains | Buy → Buy | — | $2.54 | $2.54 | +0.0% | +1.6% | +11.2% | -0.3% | -3.5% | +0.7% |
| Sep 3 | BofA Securities | Downgrade | Buy → Underperform | — | $1.60 | $1.49 | -6.9% | -10.6% | +3.5% | +8.8% | -3.7% | +3.9% |
| Aug 18 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $1.64 | $1.53 | -6.7% | -6.7% | -0.7% | -3.9% | +2.7% | +6.7% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.43 | $1.39 | -2.8% | +2.1% | +2.1% | +6.0% | -8.2% | -13.8% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | +3.4% | -2.6% | -0.7% | +0.0% | +4.7% |
| Mar 21 | Goldman Sachs | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | +3.4% | -2.6% | -0.7% | +0.0% | +4.7% |
| Jan 7 | BofA Securities | Upgrade | Neutral → Buy | — | $2.67 | $2.82 | +5.6% | +3.0% | +0.0% | -13.8% | -9.3% | -10.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.06 | +2.3% | -4.7% | -1.4% | -5.0% | +2.2% | +2.2% |
| Oct 25 | Goldman Sachs | Maintains | Buy → Buy | — | $2.58 | $2.66 | +3.1% | +2.3% | +0.0% | +6.1% | -3.6% | -4.1% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $2.66 | +3.1% | +2.3% | +0.0% | +6.1% | -3.6% | -4.1% |
| Aug 14 | Goldman Sachs | Maintains | Buy → Buy | — | $2.60 | $2.59 | -0.4% | -0.4% | +4.6% | +3.3% | -1.8% | +0.7% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.59 | $2.70 | +4.2% | +0.4% | -0.4% | +4.6% | +3.3% | -1.8% |
| May 28 | Goldman Sachs | Maintains | Buy → Buy | — | $2.63 | $2.60 | -1.1% | -4.2% | -4.4% | +2.9% | +1.6% | +2.4% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $1.87 | -5.1% | +13.7% | +4.9% | +3.8% | +6.1% | +1.5% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.14 | -0.5% | -8.8% | -5.6% | +2.7% | -2.1% | +1.6% |
| Apr 2 | Goldman Sachs | Maintains | Buy → Buy | — | $2.16 | $2.08 | -3.7% | -0.5% | +0.9% | -3.7% | +0.5% | +6.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.42 | +17.5% | +0.0% | +4.9% | -0.5% | +0.9% | -3.7% |
| Jan 5 | BofA Securities | Downgrade | Buy → Neutral | — | $2.16 | $2.07 | -4.2% | -5.6% | +5.9% | -2.3% | -0.9% | -6.7% |
| Nov 29 | Mizuho | Maintains | Buy → Buy | — | $1.99 | $2.00 | +0.8% | -9.8% | -5.0% | -1.8% | +0.6% | +4.2% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.30 | +2.7% | -11.4% | -9.8% | -5.0% | -1.8% | +0.6% |
| Jun 6 | Mizuho | Maintains | Buy → Buy | — | $3.30 | $3.25 | -1.5% | -8.2% | -7.6% | -2.9% | +8.5% | -1.4% |
| Jun 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $3.30 | $3.25 | -1.5% | -8.2% | -7.6% | -2.9% | +8.5% | -1.4% |
| May 16 | Goldman Sachs | Maintains | Buy → Buy | — | $2.96 | $2.94 | -0.7% | -4.1% | +1.4% | -4.2% | +0.0% | +5.8% |
| Mar 30 | Mizuho | Maintains | Buy → Buy | — | $2.96 | $3.16 | +6.8% | -2.0% | +3.8% | +4.7% | -7.3% | +1.0% |
| Feb 24 | Goldman Sachs | Maintains | Buy → Buy | — | $3.57 | $3.74 | +4.8% | +0.6% | +0.3% | +0.0% | -2.8% | -4.9% |
| Feb 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $4.15 | $4.49 | +8.2% | +4.8% | -2.5% | -0.7% | -4.8% | -1.7% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $21.15 | $21.48 | +1.6% | -4.3% | +3.8% | -8.1% | +3.9% | -2.8% |
| Aug 10 | Guggenheim | Maintains | Buy → Buy | — | $21.15 | $21.48 | +1.6% | -4.3% | +3.8% | -8.1% | +3.9% | -2.8% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.15 | $21.48 | +1.6% | -4.3% | +3.8% | -8.1% | +3.9% | -2.8% |
| Aug 10 | Evercore ISI | Maintains | Outperform → Outperform | — | $21.15 | $21.48 | +1.6% | -4.3% | +3.8% | -8.1% | +3.9% | -2.8% |
| Aug 10 | BofA Securities | Maintains | Buy → Buy | — | $21.15 | $21.48 | +1.6% | -4.3% | +3.8% | -8.1% | +3.9% | -2.8% |
No insider trades available.
8-K · 8.01
!! High
Erasca, Inc. -- 8-K 8.01: Material Event / Announcement
Erasca received a legal letter from Revolution Medicines alleging infringement on ERA assets, representing potential intellectual property litigation that could impact Erasca's product development pipeline and valuation.
Apr 27
8-K
Erasca, Inc. -- 8-K Filing
Erasca's KRAS inhibitor candidate demonstrated favorable pharmacokinetics with a defined active dose range of 16-32 mg daily without plateau effects, supporting advancement toward clinical development.
Apr 27
8-K · 8.01
!! High
Erasca, Inc. -- 8-K 8.01: Material Event / Announcement
This boilerplate safe harbor disclosure indicates ERAS made forward-looking statements in an 8-K filing, protecting the company from litigation if projections don't materialize, which is standard but suggests caution about recent claims made.
Apr 21
8-K
Unknown — 8-K Filing
ERA Oncology's rapidly advancing RAS-targeting pipeline with strong clinical momentum suggests meaningful near-term data catalysts that could validate its precision oncology strategy and drive stock appreciation if trials succeed.
Mar 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 16,157,175 | $261M | Added | Mar 2026 |
| 2 | Vivo Capital, Llc | 12,151,480 | $197M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 11,249,738 | $182M | New | Mar 2026 |
| 4 | Vr Adviser, Llc | 17,857,083 | $66M | — | Dec 2025 |
| 5 | Janus Henderson Group Plc | 3,710,966 | $60M | New | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 3,055,897 | $49M | Added | Mar 2026 |
| 7 | Woodline Partners Lp | 2,831,538 | $46M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 1,848,580 | $30M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 1,773,757 | $29M | New | Mar 2026 |
| 10 | Northern Trust Corp | 1,701,623 | $28M | Added | Mar 2026 |
| 11 | Victory Capital Management Inc | 1,654,497 | $27M | Added | Mar 2026 |
| 12 | Fmr Llc | 1,490,080 | $24M | Added | Mar 2026 |
| 13 | Renaissance Technologies Llc | 1,398,869 | $23M | Added | Mar 2026 |
| 14 | D.e. Shaw & Co | 1,219,534 | $20M | Added | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 1,087,301 | $18M | Added | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 924,405 | $14M | Reduced | Mar 2026 |
| 17 | Invesco Ltd. | 759,932 | $12M | Added | Mar 2026 |
| 18 | Point72 Asset Management | 693,309 | $11M | New | Mar 2026 |
| 19 | Aqr Capital Management Llc | 691,205 | $11M | Added | Mar 2026 |
| 20 | Millennium Management | 575,996 | $9M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$4.25B
Enterprise Value
$3.60B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.23x
P/B
11.92x
P/S
—
P/FCF
-40.55x
EV/EBITDA
—
Shares Out
283.5M
Financials (TTM)
Revenue
$0
Net Income
-$277.0M
EBITDA
-$270.8M
Free Cash Flow
-$95.6M
Op Cash Flow
-$95.5M
EPS Basic
$-0.44
EPS Diluted
$-0.93
EPS Forward
$-0.44
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$396.2M
Total Liab.
$71.0M
Total Equity
$325.2M
Cash
$276.1M
LT Debt
$0
Book Value/Sh
$1.15
Debt/Equity
0.14x
Current Ratio
10.04
Quick Ratio
10.04
Returns & Growth
ROE
-38.3%
ROA
-31.4%
ROIC
-35.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+36.2%
Price Returns
2W
+23.8%
1M
+20.6%
3M
-6.0%
6M
+305.0%
12M
+817.1%
Technicals
52W High
$24.28
52W Low
$1.21
50d MA
$13.77
200d MA
$8.55
RSI (14)
55.50
ATR (14)
$1.14
Beta
1.05
Avg Volume
4.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$13.60
High
$30.00
Low
$5.00
Median
$11.00
Data updated apr 25, 2026 7:33am
· Source: financialmodelingprep.com